Cytokinetics reported total revenues of $1.9 million for the third quarter of 2025, up from $0.5 million in the same period in 2024. Research and development expenses were $99.2 million, including $15.1 million in non-cash stock-based compensation, compared to $84.6 million in the prior year period. General and administrative expenses rose to $69.5 million, including $15.6 million in non-cash stock-based compensation, from $56.7 million in the third quarter of 2024. The company reported a net loss of $306.2 million, or $(2.55) per share, compared to a net loss of $160.5 million, or $(1.36) per share, for the same quarter last year. The net loss includes a debt conversion expense of $121.2 million related to the induced exchange of the 2027 Notes. As of September 30, 2025, Cytokinetics had approximately $1.25 billion in cash, cash equivalents, and investments. Key business developments include progress toward the December 26, 2025 PDUFA date for aficamten, ongoing regulatory reviews in China and the European Union, and continued commercial launch preparations in the U.S.